ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2014
AMPK activation: a therapeutic target for type 2 diabetes?
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
202 citing papers in PubMed, 3 syntheses or guidelines pooled it, 429 citations in OpenAlex.
- Pooled it
- Metformin and heart failure-related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials.Heart failure reviews · 2021Pooled it
- Effects ofInternational journal of environmental research and public health · 2019Pooled it
- Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study.Diabetologia · 2019Trial
- Abundance in proteins expressed after functional electrical stimulation cycling or arm cycling ergometry training in persons with chronic spinal cord injury.The journal of spinal cord medicine · 2017Trial
- Long-term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study.International journal of urology : official journal of the Japanese Urological Association · 2015 · on this mapTrial
- Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation.International journal of molecular sciences · 2026Review
- AMPK Therapy-A Little Goes A Long Way.Cells · 2026Review
- Prediabetes in children and adolescents: what do we need to know?Annals of pediatric endocrinology & metabolism · 2026Article
- Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.International journal of molecular sciences · 2026Review
- Oxidative stress and the therapeutic potential of dietary antioxidants in polycystic ovary syndrome: a narrative review.Journal of ovarian research · 2026Review
- Bifidobacterium's Influential Role in the Battle Against Obesity: Going Beyond Probiotics.Probiotics and antimicrobial proteins · 2026Review
- The Relationship Between Aldose Reductase and Isoxazole Derivatives: An In Vitro and In Silico Approach to Its Correlation With Diabetic Conditions.Biotechnology and applied biochemistry · 2026Article
- Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus.Pharmaceutics · 2026Review
- Review
- Research Hotspots, Trends, and Molecular Mechanisms of Diabetes and Sarcopenia: A Bibliometric and Bioinformatics Analysis.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Impact of Combination Therapy With Caffeine and Naringin on Insulin Resistance and Renal Function in a Nonalcoholic Fatty Liver Disease Rat Model.BioMed research international · 2026Article
- Alteration of metabolic activity regulates mitochondrial temperature in diagnosis in HepG2 hepatocellular carcinoma cells.Scientific reports · 2025Article
- Taurine in Type 2 Diabetes: Plasma Concentrations, Metabolic Pathways, and Potential as a Therapeutic Adjuvant.Current nutrition reports · 2025Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have T2D, and the International Diabetes Federation projects that this number will increase to nearly 600 million by 2035. There is a great need for more effective treatments for maintaining glucose homeostasis and improving insulin sensitivity. AMP-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase whose activation elicits insulin-sensitizing effects, making it an ideal therapeutic target for T2D. AMPK is an energy-sensing enzyme that is activated when cellular energy levels are low, and it signals to stimulate glucose uptake in skeletal muscles, fatty acid oxidation in adipose (and other) tissues, and reduces hepatic glucose production. There is substantial evidence suggesting that AMPK is dysregulated in animals and humans with metabolic syndrome or T2D, and that AMPK activation (physiological or pharmacological) can improve insulin sensitivity and metabolic health. Numerous pharmacological agents, natural compounds, and hormones are known to activate AMPK, either directly or indirectly - some of which (for example, metformin and thiazolidinediones) are currently used to treat T2D. This paper will review the regulation of the AMPK pathway and its role in T2D, some of the known AMPK activators and their mechanisms of action, and the potential for future improvements in targeting AMPK for the treatment of T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.